BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
A phase 1/2 trial of BCMA CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.
Overview
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease is a phase 1/2 interventional study registered as NCT04271644 by Chongqing Precision Biotech Co., Ltd, with 80 participants planned, started 2019-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: BCMA CAR-T cells.
Similar pages
not linked directly; found by shared links- Triala Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Shares Chongqing Precision Biotech, Multiple myeloma and the tag pipeline.
- TrialA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Shares Chongqing Precision Biotech and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.